The gastrointestinal microbiota can effect the development of RA as a result of proximal intestinal immunomodulatory cells, which happen to be located in specific locations inside the intestine. The latest therapeutic approach to RA authorised with the FDA and EMA involves the use of JAKi. These molecules are divided into https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/